TBA 7371

Drug Profile

TBA 7371

Alternative Names: TBA-7371

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; Global Alliance for TB Drug Development
  • Developer Global Alliance for TB Drug Development
  • Class Antituberculars; Indoles
  • Mechanism of Action DprE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 01 Aug 2017 Phase-I clinical trials in Tuberculosis (In volunteers) in USA (PO) (NCT03199339)
  • 29 Jul 2017 Global Alliance for TB Drug Development plans a phase I trial of TBA 7371 (In volunteers) for Tuberculosis in USA (NCT03199339)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top